{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:47:34Z","timestamp":1780379254767,"version":"3.54.1"},"reference-count":31,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients immediately post-hematopoietic cell transplantation are at high risk for bacteremia. Judicious prophylactic antimicrobial utilization must balance anticipated benefits (reduction infections) versus risk (bacterial resistance, Clostridium difficile) .<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare infectious outcomes (primary: incidence bacteremia; secondary: febrile neutropenia, C. difficile, susceptibility of bacteremia, time to discharge and 30-day mortality) between hematopoietic cell transplantation who received fluoroquinolone prophylaxis to those who did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A local institutional review board-approved retrospective study was conducted on all hematopoietic cell transplantation patients ( n\u2009=\u2009171) comparing those who received fluoroquinolone prophylaxis ( n\u2009=\u2009105) to those who did not ( n\u2009=\u200966). Data included infectious outcomes and mortality for the first 30 days post-hematopoietic cell transplantation. Chi-squared was performed for categorical variables (GraphPad Software Inc., 2015). Secondary analysis compared outcomes within autologous and allogeneic sub-groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Bacteremia was significantly lower for the overall cohort receiving fluoroquinolone (median duration eight days) versus those without fluoroquinolone (15.2% vs. 31.8%; P\u2009&lt;\u20090.01). No difference was seen in C. difficile infection ( P\u2009=\u20090.81) or 30-day mortality (2.9% vs. 4.5%; P\u2009=\u20090.67). In the autologous sub-group ( n\u2009=\u2009115), bacteremia was significantly lower in the fluoroquinolone cohort (8.5% vs. 27.3%; P\u2009=\u20090.0069), while no differences were seen in C. difficile infection ( P\u2009=\u20091) or 30-day mortality ( P\u2009=\u20091). In the allogeneic sub-group ( n\u2009=\u200956), there was no difference between those with and without fluoroquinolone in bacteremia (29.4% vs. 40.9%; P\u2009=\u20090.4) or C. difficile ( P\u2009=\u20090.72); however, there was a trend toward improved 30-day mortality (2.9% vs. 9.1%; P\u2009=\u20090.55).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fluoroquinolone prophylaxis reduces incidence of bacteremia in autologous hematopoietic cell transplantation without increasing C. difficile after hematopoietic cell transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155217735153","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T13:44:31Z","timestamp":1508766271000},"page":"326-332","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of fluoroquinolone prophylaxis on infectious-related outcomes after hematopoietic cell transplantation"],"prefix":"10.1177","volume":"25","author":[{"given":"Amber B","family":"Clemmons","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Georgia, Augusta, GA USA"},{"name":"Georgia Cancer Center, Augusta, GA, USA"},{"name":"Department of Pharmacy, Augusta University Medical Center, Augusta, GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita S","family":"Gandhi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Georgia, Augusta, GA USA"},{"name":"Department of Pharmacy, Augusta University Medical Center, Augusta, GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Albrecht","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Georgia, Augusta, GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta, GA, USA"},{"name":"Department of Medicine, Augusta University Medical Center, Augusta, GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Pantin","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta, GA, USA"},{"name":"Department of Medicine, Augusta University Medical Center, Augusta, GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"bibr1-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.02.013"},{"key":"bibr2-1078155217735153","author":"Kedia SAP","year":"2013","journal-title":"Stem Cell Res Ther"},{"key":"bibr3-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"bibr4-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.006"},{"key":"bibr5-1078155217735153","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: prevention and treatment of cancer related infections. Version 2, www.nccn.org (2015, accessed 8 January 2016)."},{"key":"bibr6-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq147"},{"key":"bibr7-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.06.016"},{"key":"bibr8-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.03.006"},{"key":"bibr9-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044097"},{"key":"bibr10-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.4.795"},{"key":"bibr11-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704423"},{"key":"bibr12-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf009"},{"key":"bibr13-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705591"},{"key":"bibr14-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.12.010"},{"key":"bibr15-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"bibr16-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31827e83af"},{"key":"bibr17-1078155217735153","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008"},{"key":"bibr18-1078155217735153","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","volume":"142","author":"Gafter-Gvili A","year":"2005","journal-title":"Ann Intern Med"},{"key":"bibr19-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703366"},{"key":"bibr20-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22205"},{"key":"bibr21-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.06.017"},{"key":"bibr22-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212465215"},{"key":"bibr23-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12175"},{"key":"bibr24-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12237"},{"key":"bibr25-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.2_suppl.397S"},{"key":"bibr26-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703413"},{"key":"bibr27-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.286"},{"key":"bibr28-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2311"},{"key":"bibr29-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.02.006"},{"key":"bibr30-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701996"},{"key":"bibr31-1078155217735153","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704108"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217735153","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217735153","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217735153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:44Z","timestamp":1777688264000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217735153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1177\/1078155217735153"],"URL":"https:\/\/doi.org\/10.1177\/1078155217735153","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,23]]}}}